

## Changing mortality and place of death in response to refugee influx

Guo, Ping; Chukwusa, Emeka; Asad, Majed; Nimri, Omar; Arqoub, Kamal; Alajarmeh, Sawsan; Mansour, Asem; Sullivan, Richard; Shamieh, Omar; Harding, Richard

DOI:

[10.1089/jpm.2020.0476](https://doi.org/10.1089/jpm.2020.0476)

License:

None: All rights reserved

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Guo, P, Chukwusa, E, Asad, M, Nimri, O, Arqoub, K, Alajarmeh, S, Mansour, A, Sullivan, R, Shamieh, O & Harding, R 2021, 'Changing mortality and place of death in response to refugee influx: a population-based cross-sectional study in Jordan, 2005-2016', *Journal of Palliative Medicine*, vol. 24, no. 11, pp. 1616-1625.  
<https://doi.org/10.1089/jpm.2020.0476>

[Link to publication on Research at Birmingham portal](#)

### **Publisher Rights Statement:**

Final publication is available from Mary Ann Liebert, Inc., publishers <https://doi.org/10.1089/jpm.2020.0476>

### **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### **Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

1 **Changing mortality and place of death in response to refugee influx: a population-**  
2 **based cross-sectional study in Jordan, 2005-2016**

3  
4 **Abstract**

5 **Background** Jordan faces complex healthcare challenges due to refugee influx and an  
6 ageing population. Palliative care planning and delivery require data to ensure services  
7 respond to changing population needs.

8 **Objectives** To determine the trend in mortality and place of death in Jordan.

9 **Design** Population-based study.

10 **Setting/subjects** Death registry data of adult decedents (n=143,215), 2005-2016.

11 **Measurements** Descriptive statistics examined change in demographic and place of death  
12 (categorised as hospital and non-hospital). Binomial logistic regression compared the  
13 association between hospital deaths and demographic characteristics in 2008-2010, 2011-  
14 2013, 2014-2016, with 2005-2007.

15 **Results** The annual number of deaths increased from 6,792 in 2005 to 17,018 in 2016 (151%  
16 increase). Hospital was the most common place of death (93·7% of all deaths) in Jordan,  
17 and percentage of hospital deaths increased for Jordanian (82·6%-98·8%) and non-  
18 Jordanian decedents (88·1%-98·7%). There was an increased likelihood of hospital death  
19 among Jordanian decedents who died from non-ischaemic heart disease (OR: 1·11, 95% CI:  
20 1·09-1·13,  $P<0\cdot001$ ), atherosclerosis (OR: 1·10, 95% CI: 1·08-1·13,  $P<0\cdot001$ ), renal failure  
21 (OR: 1·05, 95% CI: 1·02-1·08,  $P<0\cdot001$ ), haemorrhagic fevers (OR: 1·09, 95% CI: 1·06-1·13,  
22  $P<0\cdot001$ ), and injury (OR: 1·18, 95% CI: 1·06-1·33,  $P<0\cdot001$ ) in the period 2014-2016,  
23 compared with 2005-2007. There were similar increases in the likelihood of hospital death  
24 amongst non-Jordanians in 2014-2016 for the following conditions: malignant neoplasms  
25 (except leukaemia), non-ischaemic heart disease, atherosclerosis, injury, and HIV,  
26 compared with 2005-2007.

27 **Conclusions** Country-level palliative care development must respond to both internal  
28 (ageing) and external (refugee influx) population trends. Universal Health Coverage requires

29 palliative care to move beyond cancer and meet population-specific needs. Community-  
30 based services should be prioritised and expanded to care for the patients with non-  
31 ischaemic heart disease, atherosclerosis, renal failure, haemorrhagic fevers, and injury.

32

33

## 34 **Introduction**

35 Palliative care is a human right.<sup>1</sup> Universal Health Coverage (UHC)<sup>2</sup> and the World Health  
36 Assembly (WHA) Resolution 67.19<sup>3</sup> call for palliative care to be integrated into national  
37 health services, accessible globally for all individuals and communities in need. However,  
38 palliative care and pain relief were identified as neglected dimensions of global health by the  
39 Lancet Commission on Global Access to Palliative Care and Pain Relief.<sup>4</sup> Only 10% of the  
40 20 million people each year who need palliative care actually receive it, and 80% of this  
41 need is in low- and middle-income countries (LMICs).<sup>5</sup> The WHO Global Atlas reports that  
42 only 30 countries (15%) in the world have fully integrated palliative care into their national  
43 healthcare systems, and 47 countries (24%) have no known hospice-palliative care activity.<sup>6</sup>

44

45 By 2060, there will be an estimated 48 million people who will die each year with serious  
46 health-related suffering.<sup>7</sup> The vast majority of these deaths (83%) will occur in LMICs, an  
47 increase of 94% between 2016 and 2060. These increases are primarily in cancer<sup>8</sup>,  
48 cerebrovascular disease, lung disease and dementia. Progressive illness in LMIC places a  
49 huge burden on patients and (largely female) family caregivers<sup>9,10</sup>, and costs in the final year  
50 of life, accounting for 20% of health spending.<sup>11</sup>

51

52 Jordan faces a complex refugee situation, hosting the second-greatest ratio of refugees to  
53 citizens of any country in the world.<sup>12</sup> Although Jordan is a non-signatory state to the  
54 Refugee Convention, it has received millions of refugees over the years: Somalians,  
55 Sudanese, Chechens, Circassians, Armenians, Palestinians (the most majority of the  
56 refugee population), Mandeans, Iraqis and, most recently, Syrians.<sup>13,14</sup> Since the outbreak of

57 political violence in Syria in 2011, Jordan is grappling with the challenge of accommodating  
58 significant numbers of Syrian refugees over the long term. Even though international NGOs  
59 and local social workers have begun to develop intervention plans for Syrian refugees in  
60 camps, the large majority of Syrian refugees (84%) live outside refugee camps in Jordanian  
61 communities.<sup>15</sup> Compared to the other neighbouring countries hosting Syrian refugees  
62 (Lebanon, Iraq, and Turkey), Jordan hosts the highest number of urban Syrian refugees, and  
63 the constant influx of Palestinian, Syrian, and Iraqi refugees has placed considerable strain  
64 on its capacity to ensure regular and effective access to basic services.<sup>16</sup>

65

66 Jordan has a population of approximately 10 million people and faces unique and complex  
67 challenges in health care due to the refugee influx<sup>12,16,17</sup> and rising incidence of cancer.<sup>18-20</sup>  
68 As of September 2016, over 656,000 Syrian refugees were registered with the United  
69 Nations High Commissioner for Refugees (UNHCR) in Jordan, accounting for approximately  
70 10% of Jordan's native resident population. The annual cost of providing cancer care to  
71 Syrian refugees in Jordan in 2017 was estimated at €2.09 million, which represents a  
72 significant financial burden for the host country.<sup>21</sup>

73

74 The development of palliative care in Jordan is still in its infancy, and many challenges  
75 persist in promoting palliative care at the national level.<sup>18,19,22</sup> These include: (1) Lack of  
76 national palliative care strategy implementation, with resource allocation heavily skewed to  
77 curative and acute care, compared to palliative care; (2) Negative public and healthcare  
78 provider attitudes towards palliative care and delayed referral; (3) Constraints in opioids  
79 prescribing and supply; (4) Concealment of diagnosis and prognosis to patients; (5) Unmet  
80 psychosocial and family support needs; (6) Research on palliative care is limited. Palliative  
81 care began in Jordan several decades ago<sup>23</sup>, and is provided in a comprehensive centre of  
82 excellence and across the public health system.<sup>22,24</sup> The Jordan Palliative Care Society  
83 (JPCS) initiatives aim to expand, develop, and rehabilitate the Oncology Department and  
84 Palliative Care Services across eight public hospitals.<sup>25-27</sup>

85

86 The number of refugees registered in Jordan currently stands at 744,795 persons of concern,  
87 among a Jordanian population of 10 million people.<sup>28</sup> The influx of refugees from  
88 neighbouring countries (i.e. Palestine, Syria, and Iraq) has placed additional strain on health  
89 systems and budgets.<sup>29</sup> Palliative care provision and planning require data to ensure that  
90 services respond to changing population needs. This study aimed to determine the trends in  
91 mortality and place of death in Jordan for both Jordanian and non-Jordanian decedents for  
92 the years 2005-2016.

93

## 94 **Methods**

### 95 **Study design and settings**

96 A population-based study using routine anonymised death registry data in Jordan. The study  
97 was approved by the Research Ethics Committee at King's College London (Reference no.  
98 HR-17/18-7243), Jordanian Ministry of Health (Reference no. MOH REC 1800110) and King  
99 Hussein Cancer Centre in Jordan (Reference no. 18KHCC70).

100

### 101 **Data sources**

102 Data for all adult deaths (aged 18 years and above) registered in Jordan from 2005 to 2016  
103 inclusive were obtained from the Ministry of Health, Jordan. The data included age (an  
104 ordered categorical variable, 25-54, 55-64, 65-74, 75-84 and 85+), gender (men, women),  
105 marital status (married, single, divorced, widowed, and other), underlying cause of death  
106 (CoD), country of origin, place of death, and year of death of the deceased persons in  
107 Jordan.

108

109 CoD was recorded according to the 10th revision of the International Classification of  
110 Diseases (ICD-10) codes<sup>30</sup>, and categorised into the 20 health conditions most commonly  
111 requiring palliative care, defined by the Lancet Commission on Palliative Care and Pain

112 Relief (Table 1).<sup>4</sup> Decedent country of origin was stratified into Jordanian and non-Jordanian  
113 (refugees who migrated from other countries but died in Jordan between 2005 and 2016).  
114 Place of death was grouped into hospital (including deaths in private and public hospitals)  
115 and non-hospital deaths (deaths at home or other places).

116

## 117 **Analysis**

118 Patients' sociodemographic characteristics were presented using descriptive statistics.  
119 Percentage trends in hospital and non-hospital deaths for Jordanians and non-Jordanians  
120 were plotted against the year of death (2005-2016) using a line graph. Data were grouped  
121 into four time periods: 2005-2007, 2008-2010, 2011-2013 and 2014-2016 to examine the  
122 changing trends in hospital deaths and patients' sociodemographic characteristics. The cut-  
123 off boundaries for four time periods were based on the data distribution considering the start  
124 of the Syrian civil war in 2011.

125

126 Binomial logistic regression was used to estimate the association between hospital deaths  
127 and patient demographic characteristics. We developed three models separately, and each  
128 model compared the association between patients' demographic characteristics and hospital  
129 deaths for Jordanians and non-Jordanians. The dependent variable consisted of hospital  
130 deaths in 2005-2007 (0), compared with other periods 2008-2010 (1), 2011-2013 (1), and  
131 2014-2016 (1). All explanatory variables (age, gender, CoDs, marital status) were forced to  
132 remain in the model. Odd Ratios (OR) and 95% confidence intervals (95% CI) were used to  
133 quantify the association between hospital deaths and patients' demographic characteristics.  
134 Bonferroni correction was applied to adjust for family-wise error rate (0·05/6). All statistical  
135 analyses were completed using R Version 3·5·2.

136

## 137 **Results**

138 A total of N=143,215 people aged 18 years or above died in Jordan between 2005 and 2016  
139 inclusive (Table 1). The annual number of deaths increased from 6,792 in 2005 to 17,018 in  
140 2016 (an 151% increase). The majority of the decedents were male (55.8% - 58.0%)  
141 (Appendix 1). The top leading CoD across all years were malignant neoplasms (except  
142 leukaemia) (17.4%), chronic ischaemic heart diseases (13.6%), cerebrovascular diseases  
143 (12.4%), and non-ischaemic heart diseases (10.9%), followed by atherosclerosis (6.7%),  
144 liver diseases (3.5%), lung diseases (3.3%), and renal failure (3.3%). Figure 1 shows the  
145 percentages of deaths by country of origin (Jordanian and non-Jordanian decedents)  
146 stratified by the leading CoD between 2005 and 2016.

147

148 In terms of country of origin, the proportion of total deaths for non-Jordanians increased from  
149 6.4% (n=1974) in 2008-2010 to 7.2% (n=2917) in 2011-2013. This increase corresponds  
150 with the period of the Syrian civil war, which started from 15<sup>th</sup> March 2011. Hospital was the  
151 most common place of death. The percentage of deaths at hospitals increased over time for  
152 both Jordanian (82.6% in 2005 to 98.8% in 2016) and non-Jordanian population (88.1% in  
153 2005 to 98.7% in 2016) (Figure 2).

154

155 Results from binomial logistic regression showed a decreased likelihood (OR: 0.91, 95% CI:  
156 0.88-0.94,  $P<0.001$ ) of hospital deaths among Jordanian decedents aged 75-84 who died  
157 within the period 2014-2016, compared with 2005-2007. There was also a similar decrease  
158 in the likelihood of hospital deaths (OR: 0.91, 95% CI: 0.88-0.95,  $P<0.001$ ) for Jordanian  
159 aged 85 year and above (Table 2). By contrast, there was an increased likelihood of hospital  
160 deaths amongst non-Jordanians aged 75-84 years (OR: 1.03, 95%CI: 0.94-1.13,  $P=1.00$ )  
161 and in the oldest age group (85+) (OR: 1.02, 95% CI: 0.92-1.13,  $P=1.00$ ) for the period  
162 2014-2016, compared with 2005-2007, but this result was not statistically significant (Table  
163 3). Regarding marital status, there was an increased likelihood of hospital deaths among  
164 Jordanian decedents who were married (OR: 1.10, 95% CI: 1.08-1.13,  $P<0.001$ ), divorced  
165 (OR: 1.47, 95% CI: 1.39-1.56,  $P<0.001$ ), or widowed (OR: 1.49, 95% CI: 1.44-1.54,

166  $P<0\cdot001$ ), for the period 2014-2016, compared with 2005-2007 (Table 2). The similar pattern  
167 was found among non-Jordanians, but the result was not statistically significant (Table 3).

168

169 Among Jordanian decedents in the period 2014-2016, there was an increased likelihood of  
170 hospital deaths from non-ischaemic heart disease (OR: 1·11, 95% CI: 1·09-1·13,  $P<0\cdot001$ ),  
171 atherosclerosis (OR: 1·10, 95% CI: 1·08-1·13,  $P<0\cdot001$ ), renal failure (OR: 1·05, 1·02-1·08,  
172  $P<0\cdot001$ ), haemorrhagic fevers (OR: 1·09, 95% CI: 1·06-1·13,  $P<0\cdot001$ ), and injury (OR:  
173 1·18, 95% CI: 1·06-1·33,  $P<0\cdot001$ ), compared with 2005-2007. For non-Jordanian  
174 decedents in 2014-2016, the non-significant increases in CoD were found for malignant  
175 neoplasms (except leukaemia), non-ischaemic heart disease, atherosclerosis, injury, and  
176 HIV (Table 2 and 3).

177

## 178 **Discussion**

179 This is the first population-based study to determine changing demographics, place of death,  
180 and CoD in a country with a large refugee influx. An increase was found in the proportion of  
181 total deaths for non-Jordanians from 6·4% ( $n=1974$ ) in 2008-2010 to 7·2% ( $n=2917$ ) in 2011-  
182 2013, which corresponds with the period of the Syrian civil war. This represented a 47·8%  
183 increase in the number of deaths in Jordan for non-Jordanians. Among Jordanian decedents  
184 in the period 2014-2016, there was a significantly increased likelihood of hospital deaths  
185 from non-ischaemic heart disease, atherosclerosis, renal failure, haemorrhagic fevers, and  
186 injury, compared with 2005-2007. For non-Jordanian decedents in 2014-2016, the increase  
187 in CoD were malignant neoplasms (except leukaemia), non-ischaemic heart disease,  
188 atherosclerosis, injury, and HIV, however neither was statistically significant. Community-  
189 based services should be developed to prioritise care for these conditions.

190

191 Hospital was the most common place of death (93·7%) among all deaths. During the study  
192 period, the percentage of hospital deaths increased for both Jordanian (from 82·6% in 2005  
193 to 98·8% in 2016) and non-Jordanian population (from 88·1% in 2005 to 98·7% in 2016).



194 Contrary to previous studies conducted in European countries<sup>31,32</sup>, our results indicate that  
195 the likelihood of hospital deaths increased amongst Jordanian and non-Jordanians during  
196 the period 2014 -2016. The dramatic increase in hospital deaths may be due to  
197 epidemiologic transition in the population structure induced by the increase in non-  
198 communicable diseases<sup>33</sup> and other factors such as improved reporting of mortality data<sup>34</sup>  
199 and lack of community-based services in Jordan (lack of supply of the home care services  
200 and stand-alone hospices and nursing homes).<sup>22</sup> And it also could be that the cost of home  
201 care service provision is usually covered out of pocket and not reimbursed by public or  
202 private insurance in Jordan.

203  
204 Palliative care in Jordan is mostly delivered in hospitals, and mainly focus on cancer  
205 patients.<sup>22</sup> A recent study, which analysed routinely collected data comprising 630 patients  
206 with cancer (including Jordanian and non-Jordanian) referred to the palliative care service at  
207 KHCC and died between 1<sup>st</sup> January 2011 and 31<sup>st</sup> December 2012, showed that over 87.3%  
208 died in hospitals.<sup>35</sup> Hospital deaths are more prevalent than home deaths in cancer patients  
209 in Jordan. This phenomenon that families transfer the patients to the hospital when they are  
210 getting terminal is most likely attributed to a lack of afterhours and extended home care  
211 coverage, and the costs of hospitalisations covered by the public and private insurance for  
212 cancer patients. This study found that male patients, aged over 65 years, with earlier  
213 palliative care involvement, and involvement of home care services were significantly  
214 associated with dying at home.<sup>35</sup> We also found a decreased likelihood in hospital deaths  
215 amongst older Jordanians aged 75 years and above. It is consistent with the results of the  
216 above retrospective analysis of 630 cancer patients who received palliative care at KHCC  
217 which showed that home death is more likely amongst older age group in Jordan, especially  
218 those with cancer.<sup>35</sup> The decreased likelihood of hospital deaths for those aged 75 years  
219 may be partly due to patients' preference for home deaths or the influence of palliative care  
220 programmes, designed to encourage out-of-hospital deaths.<sup>22,36</sup>

221

222 Although the number of deaths per year have increased globally<sup>37</sup>, palliative care is not  
223 widely available. There is no structured palliative care programme operating outside  
224 Jordan's capital Amman. Within Amman, these services are primarily limited to the private  
225 sector and cancer care.<sup>18,22</sup> In the public sector, the oncology team at the government  
226 hospital of Al-Bashir in Amman recently began offering palliative care to cancer patients  
227 within limited resources.<sup>38</sup> Now is the time to promote contextually appropriate palliative care  
228 development, addressing the needs of refugees and people with cancer and non-cancer  
229 conditions, particularly those with cardiovascular diseases. We found an increased likelihood  
230 of dying in hospitals from non-ischaemic heart disease and atherosclerosis in the period  
231 2014-2016, compared with 2005-2007, among Jordanians and non-Jordanians. This finding  
232 confirms that palliative care should not only focus on people with advanced cancer, but it  
233 also needs to extend to benefit people with other progressive illness. This is crucial given the  
234 projection data for death with serious health-related suffering.<sup>8,39</sup>

235

236 Refugees, as a minority group in any society, experience many stressful and traumatic  
237 situations prior to, during, and after transfer.<sup>40</sup> The challenges and difficulties they face  
238 include family disturbances, the loss of close relatives, unsafe situations, physical and  
239 sexual abuse, bombing, arrest, and torture,<sup>41,42</sup> social exclusion or discrimination after  
240 migration caused by their exclusion from the social system, lack of social status, increased  
241 rates of unemployment, and financial difficulties associated with low levels of services and  
242 lack of social containment.<sup>43-45</sup> In addition, refugees are exposed to posttraumatic stress  
243 disorder, depression, and anxiety.<sup>46-48</sup> The prevalence of psychological distress and mental  
244 disorders among refugees indicates that they have poor coping mechanisms and need  
245 professional assistance to cope with their stressful situations effectively.<sup>49</sup> These data  
246 suggest that the palliative care needs of these populations are likely to be more complex.

247

248 Many refugees with serious health problems experienced significant physical, emotional, and  
249 social suffering due to a lack of access to pain and symptom relief and other essential

250 components of palliative care.<sup>24,50</sup> Palliative care delivery for refugees must happen within a  
251 wider context of poor refugees' access to healthcare. There is a growing body of literature  
252 demonstrating the barriers in access to health care services among refugees, particularly  
253 those with older age.<sup>51,52</sup> Practical barriers impede access to health services for refugees,  
254 including inadequate information and awareness about the availability of services,  
255 insufficient financial support, restricted access to transport, culturally insensitive care, and  
256 inadequate provision of interpreters.<sup>53</sup> Developing and evaluating effectiveness of palliative  
257 care models in conflict-affected areas is a priority.<sup>54</sup>

258

259 Although the Global Humanitarian Response Plan for COVID-19 includes a strategic  
260 framework, countries in conflict and those experiencing humanitarian emergencies have  
261 fragile health systems and limited capacity to contain the COVID-19 spread and treat  
262 existing cases.<sup>55</sup> A modelling study<sup>56</sup> suggests that after a single infectious person enters a  
263 refugee camp, over 70%–98% of the population is likely to be infected within the first year,  
264 and a large number of deaths is expected should no effective interventions be in place. Due  
265 to the gradual easing of lockdown measures in June in Jordan, there has been a steady  
266 increase of confirmed cases across the country, reaching its largest refugee camp - Zaatari  
267 refugee camp (hosting around 76,000 Syrian refugees) in which seven persons have been  
268 tested positive for COVID-19 as of 29<sup>th</sup> October 2020. The recent emergence of COVID-19  
269 in Zaatari camp and the consequent restrictions, coupled with high density, limited WASH  
270 facilities and health services, have added another layer of complexity for refugees who have  
271 been living away from home for years.<sup>57</sup> In the refugee camps in Jordan, palliative care  
272 services were provided mainly through NGOs, and the locally trained staff in the  
273 neighbouring community clinics. Some strategies applied during the pandemic included the  
274 use of telemedicine palliative care clinics, local delivery of medications to avoid crowdedness,  
275 and occasionally home care visits.<sup>58,59</sup>

276

277 **Strengths and limitations**

278 The analysis of a whole population data set is a strength of this study. However, there are  
279 some limitations. Firstly, the method relies on data accuracy. Second, the data were limited  
280 by the variables available for analysis. For example, patient demographics such as  
281 deprivation (social-economic status or place of residence) are known to be associated with  
282 place of death<sup>60</sup> but were not available in the data set. Future studies that compare  
283 deprivation trends with regional variation in service provision and funding models should be  
284 planned. Third, no information was available on preference for place of death, symptoms,  
285 functional status, need of specialist palliative care and care trajectory, which may influence  
286 place of death. Fourth, data on place of death may not be recorded accurately. A decedent  
287 brought to hospital for certification could potentially be recorded as a hospital death.

288

## 289 **Conclusions**

290 The intersectionality of palliative care and refugee health bring a unique challenge. Palliative  
291 care services must meet the needs of people who have experienced trauma and now face  
292 end of life within social support networks that are likely to be fractured. To meet the palliative  
293 care goals of UHC, the specific dimensions of serious health-related suffering at end of life  
294 must be understood and addressed considering the changing CoD and nationality of  
295 decedents. Community based services should be prioritised and enhanced to care for all  
296 patients and their families, with specific attention to those dying with non-ischaemic heart  
297 disease, atherosclerosis, renal failure, haemorrhagic fevers, and injury.

298 **Author Contributions:**

299 RH and PG conceptualised and designed the study, with input from MA, ON, KA, SA, AM,  
300 RS, and OS. EC and PG analysed and interpreted the data. PG wrote the manuscript and  
301 EC produced the figures and tables. All authors revised the manuscript critically for important  
302 intellectual content and approved the final version.

303

304 **Data management and sharing:**

305 Data are held at Non-Communicable Diseases, Jordan Cancer Registry, The Ministry of  
306 Health (MOH), Amman, Jordan. The anonymised datasets supporting the conclusions of this  
307 manuscript are available upon request to the corresponding author.

308

309 **Conflict of Interests Disclosures:**

310 The author(s) declared no potential conflicts of interests with respect to the research,  
311 authorship and/or publication of this article.

312

313 **Funding/Support:**

314 This research is funded through the UK Research and Innovation Global Challenges  
315 Research Fund (GCRF): Research for Health in Conflict in the Middle East and North Africa  
316 (R4HC-MENA) project; developing capability, partnerships and research in the Middle East  
317 and North Africa (ES/P010962/1).

318

319 **Role of the Funder/Sponsor:**

320 The study funder/sponsor had no role in in study design; in the collection, analysis, and  
321 interpretation of data; in the writing of the report; and in the decision to submit the paper for  
322 publication. The corresponding author has full access to all the data in the study and had  
323 final responsibility for the decision to submit for publication.

324 **References**

- 325 1. Gwyther L, Brennan F, Harding R. Advancing palliative care as a human right. *J Pain Symptom*  
326 *Manage* 2009; **38**(5): 767-74.
- 327 2. World Health Organisation. Universal Health Coverage.  
328 <http://www.who.int/mediacentre/factsheets/fs395/en/> (accessed 08/02/2018).
- 329 3. World Health Organisation. The 58th World Health Assembly adopts resolution on cancer  
330 prevention and control.  
331 [http://www.who.int/mediacentre/news/releases/2005/pr\\_wha05/en/index.html](http://www.who.int/mediacentre/news/releases/2005/pr_wha05/en/index.html), 2005.
- 332 4. Knaul FM, Farmer PE, Krakauer EL, et al. Alleviating the access abyss in palliative care and  
333 pain relief-an imperative of universal health coverage: the Lancet Commission report. *Lancet* 2017.
- 334 5. World Health Organisation. Global Atlas of Palliative Care at the End of Life. Geneva, 2014.
- 335 6. Worldwide Hospice Palliative Care Alliance (WHPCA). WHO. Global atlas of palliative care.  
336 2nd Edition. 2020. <http://www.thewhpc.org/resources/global-atlas-on-end-of-life-care>
- 337 7. Sleeman KE, de Brito M, Etkind S, et al. The escalating global burden of serious health-  
338 related suffering: projections to 2060 by world regions, age groups, and health conditions. *The*  
339 *Lancet Global Health* 2019; **7**(7): e883-e92.
- 340 8. Sleeman KE, Gomes B, de Brito M, Shamieh O, Harding R. The burden of serious health-  
341 related suffering among cancer decedents: Global projections study to 2060. *Palliat Med* 2020:  
342 269216320957561.
- 343 9. Moens K, Higginson IJ, Harding R, IMPACT E. Are There Differences in the Prevalence of  
344 Palliative Care-Related Problems in People Living With Advanced Cancer and Eight Non-Cancer  
345 Conditions? A Systematic Review. *Journal of pain and symptom management* 2014.
- 346 10. Higginson I, Wade A, McCarthy M. Palliative care: views of patients and their families. *Brit*  
347 *Med J* 1990; **301**(6746): 277-81.
- 348 11. Hoover DR, Crystal S, Kumar R, Sambamoorthi U, Cantor JC. Medical expenditures during the  
349 last year of life: findings from the 1992-1996 Medicare current beneficiary survey. *Health Serv Res*  
350 2002; **37**(6): 1625-42.
- 351 12. UNHCR Jordan Factsheet - June 2017. [https://reliefweb.int/report/jordan/unhcr-jordan-](https://reliefweb.int/report/jordan/unhcr-jordan-factsheet-june-2017)  
352 [factsheet-june-2017](https://reliefweb.int/report/jordan/unhcr-jordan-factsheet-june-2017) (accessed 20 May 2018).
- 353 13. Stevens D. Legal status, labelling, and protection: the case of Iraqi 'refugees' in Jordan.  
354 *International Journal of Refugee Law* 2013; **25**(1): 1-38.
- 355 14. The World Factbook. [https://www.cia.gov/library/publications/the-world-](https://www.cia.gov/library/publications/the-world-factbook/fields/2194.html)  
356 [factbook/fields/2194.html](https://www.cia.gov/library/publications/the-world-factbook/fields/2194.html) (accessed 20 May 2018).
- 357 15. Francis A. Jordan's refugee crisis. Washington, DC: Carnegie Endowment for International  
358 Peace, 2015.
- 359 16. Eghdamian K. Religious identity and experiences of displacement: an examination into the  
360 discursive representations of Syrian refugees and their effects on religious minorities living in Jordan.  
361 *Journal of Refugee Studies* 2017; **30**(3): 447-67.
- 362 17. Lacroix M, Al-Qdah T. Iraqi refugees in Jordan: lessons for practice with refugees  
363 internationally. *European Journal of Social Work* 2012; **15**(2): 223-39.
- 364 18. Omran S, Obeidat R. Palliative care nursing in Jordan. *Journal of Palliative Care & Medicine*  
365 2015; **S4**: 005.
- 366 19. Abdel-Razeq H, Attiga F, Mansour A. Cancer care in Jordan. *Hematology/Oncology and Stem*  
367 *Cell Therapy* 2015; **8**(2): 64-70.
- 368 20. Silbermann M, Daher M, Kebudi R, Nimri O, Al-Jadiry M, Baider L. Middle Eastern conflicts:  
369 implications for refugee health in the European Union and Middle Eastern host countries. *Journal of*  
370 *global oncology* 2016; **2**(6): 422-30.
- 371 21. Abdul-Khalek RA, Guo P, Sharp F, et al. The economic burden of cancer care for Syrian  
372 refugees: a population-based modelling study. *The Lancet Oncology* 2020; **21**(5): 637-44.
- 373 22. Shamieh O, Hui D. A comprehensive palliative care program at a tertiary cancer center in  
374 Jordan. *The American journal of hospice & palliative care* 2015; **32**(2): 238-42.

- 375 23. Shamieh O, Richardson K, Abdel-Razeq H, Mansour A, Payne S. Gaining Palliative Medicine  
376 Subspecialty Recognition and Fellowship Accreditation in Jordan. *Journal of pain and symptom*  
377 *management* 2020; **60**(5): 1003-11.
- 378 24. Pinheiro I, Jaff D. The role of palliative care in addressing the health needs of Syrian refugees  
379 in Jordan. *Medicine, Conflict and Survival* 2018; **34**(1): 19-38.
- 380 25. Stjernswärd J, Ferris FD, Khleif SN, et al. Jordan palliative care initiative: a WHO  
381 Demonstration Project. *Journal of pain and symptom management* 2007; **33**(5): 628-33.
- 382 26. Bushnaq M, Fadi Abusuqair RN. Jordan palliative care and pain initiative 2011: building  
383 capacity for palliative care programs in public hospitals. *Progress in Palliative Care* 2012; **20**(4): 203-7.
- 384 27. Wright M, Wood J, Lynch T, Clark D. Mapping levels of palliative care development: a global  
385 view. *Journal of pain and symptom management* 2008; **35**(5): 469-85.
- 386 28. UNHCR. UNHCR continues to support refugees in Jordan throughout 2019.  
387 [https://www.unhcr.org/jo/12449-unhcr-continues-to-support-refugees-in-jordan-throughout-](https://www.unhcr.org/jo/12449-unhcr-continues-to-support-refugees-in-jordan-throughout-2019.html)  
388 [2019.html](https://www.unhcr.org/jo/12449-unhcr-continues-to-support-refugees-in-jordan-throughout-2019.html). 2019.
- 389 29. Stevens MR. The collapse of social networks among Syrian refugees in urban Jordan.  
390 *Contemporary Levant* 2016; **1**(1): 51-63.
- 391 30. Centers for Disease Control and Prevention. International Classification of Diseases, Tenth  
392 Revision (ICD-10). <https://www.cdc.gov/nchs/icd/icd10.htm>. 2015.
- 393 31. Gao W, Ho YK, Verne J, Glickman M, Higginson IJ. Changing patterns in place of cancer death  
394 in England: a population-based study. *PLoS Med* 2013; **10**(3): e1001410.
- 395 32. Costantini M, Camoirano E, Madeddu L, Bruzzi P, Verganelli E, Henriquet F. Palliative home  
396 care and place of death among cancer patients: a population-based study. *Palliat Med* 1993; **7**(4):  
397 323-31.
- 398 33. Al-Nsour M, Zindah M, Belbeisi A, Hadaddin R, Brown DW, Walke H. Prevalence of selected  
399 chronic, noncommunicable disease risk factors in Jordan: results of the 2007 Jordan Behavioral Risk  
400 Factor Surveillance Survey. *Prev Chronic Dis* 2012; **9**: E25-E.
- 401 34. Dababneh F, Nichols EK, Asad M, Haddad Y, Notzon F, Anderson R. Improving mortality data  
402 in Jordan: a 10 year review. *Bull World Health Organ* 2015; **93**(10): 727-31.
- 403 35. Alawneh A, Anshasi H. Place of death for patients treated at a tertiary cancer center in  
404 Jordan. *Support Care Cancer* 2020.
- 405 36. Silbermann M, Arnaout M, Daher M, et al. Palliative cancer care in Middle Eastern countries:  
406 accomplishments and challenges. *Ann Oncol* 2012; **23** Suppl 3(Suppl 3): 15-28.
- 407 37. Morris C. Universal Health Coverage and Palliative Care: Do not leave those suffering behind.  
408 2014. [http://www.thewhpc.org/images/resources/publications-](http://www.thewhpc.org/images/resources/publications-reports/Universal_health_coverage_report_final_2014.pdf)  
409 [reports/Universal\\_health\\_coverage\\_report\\_final\\_2014.pdf](http://www.thewhpc.org/images/resources/publications-reports/Universal_health_coverage_report_final_2014.pdf) (accessed 20 May 2018).
- 410 38. Wright M, Wood J, Lynch T, Clark D. Mapping levels of palliative care development: a global  
411 view. *Journal of pain and symptom management* 2008; **35**(5): 469-85.
- 412 39. Sleeman KE, de Brito M, Etkind S, et al. The escalating global burden of serious health-  
413 related suffering: projections to 2060 by world regions, age groups, and health conditions. *Lancet*  
414 *Glob Health* 2019; **7**(7): e883-e92.
- 415 40. Alzoubi FA, Al-Smadi AM, Gougazeh YM. Coping strategies used by Syrian refugees in Jordan.  
416 *Clinical Nursing Research* 2017: 1054773817749724.
- 417 41. Mohammad ASA, Issa TL, Salem GO, Fawzi AA, Ali A, Mohammed GY. Anxiety, stress, and  
418 quality of life among Iraqi refugees in Jordan: A cross sectional survey. *Nursing & Health Sciences*  
419 2017; **19**(1): 100-4.
- 420 42. Miriam S, Laura S, Morton B, Knox M, Edward M, Edward S. Impacts of a social support  
421 intervention for Somali and Sudanese refugees in Canada. *Ethnicity and Inequalities in Health and*  
422 *Social Care* 2011; **4**(4): 186-99.
- 423 43. Tippens JA. Urban Congolese refugees in Kenya: the contingencies of coping and resilience in  
424 a context marked by structural vulnerability. *Qualitative Health Research* 2017; **27**(7): 1090-103.

- 425 44. Al-Smadi AM, Tawalbeh LI, Gammoh OS, Ashour A, Alzoubi FA, Slater P. Predictors of coping  
426 strategies employed by Iraqi refugees in Jordan. *Clinical Nursing Research* 2017; **26**(5): 592-607.
- 427 45. Araya M, Chotai J, Komproe IH, de Jong JT. Quality of life after postconflict displacement in  
428 Ethiopia: comparing placement in a community setting with that in shelters. *Social psychiatry and*  
429 *psychiatric epidemiology* 2011; **46**(7): 585-93.
- 430 46. Pfortmueller CA, Schwetlick M, Mueller T, Lehmann B, Exadaktylos AK. Adult asylum seekers  
431 from the Middle East including Syria in central Europe: what are their health care problems? *PLOS*  
432 *ONE* 2016; **11**(2): e0148196.
- 433 47. Silove D, Ventevogel P, Rees S. The contemporary refugee crisis: an overview of mental  
434 health challenges. *World psychiatry : official journal of the World Psychiatric Association (WPA)* 2017;  
435 **16**(2): 130-9.
- 436 48. Sijbrandij M, Acarturk C, Bird M, et al. Strengthening mental health care systems for Syrian  
437 refugees in Europe and the Middle East: integrating scalable psychological interventions in eight  
438 countries. *European Journal of Psychotraumatology* 2017; **8**(sup2): 1388102.
- 439 49. Steel Z, Chey T, Silove D, Marnane C, Bryant RA, van Ommeren M. Association of torture and  
440 other potentially traumatic events with mental health outcomes among populations exposed to  
441 mass conflict and displacement: a systematic review and meta-analysis. *Jama* 2009; **302**(5): 537-49.
- 442 50. Doherty M, Power L, Petrova M, et al. Illness-related suffering and need for palliative care in  
443 Rohingya refugees and caregivers in Bangladesh: A cross-sectional study. *PLoS medicine* 2020; **17**(3):  
444 e1003011.
- 445 51. Miner SM, Liebel D, Wilde MH, Carroll JK, Zicari E, Chalupa S. Meeting the Needs of Older  
446 Adult Refugee Populations With Home Health Services. *Journal of Transcultural Nursing* 2015; **28**(2):  
447 128-36.
- 448 52. Kristiansen M, Razum O, Tezcan-Güntekin H, Krasnik A. Aging and health among migrants in  
449 a European perspective. *Public Health Reviews* 2016; **37**(1): 20.
- 450 53. Langlois EV, Haines A, Tomson G, Ghaffar A. Refugees: towards better access to health-care  
451 services. *Lancet (London, England)* 2016; **387**(10016): 319-21.
- 452 54. Spiegel P. It's about time for palliative care in humanitarian emergencies. *Humanitarian*  
453 *Health Digest* 2018; **1**: 3.
- 454 55. Alawa J, Alawa N, Coutts A, Sullivan R, Khoshnood K, Fouad FM. Addressing COVID-19 in  
455 humanitarian settings: a call to action. *Conflict and Health* 2020; **14**(1): 64.
- 456 56. Truelove S, Abraham O, Altare C, et al. The potential impact of COVID-19 in refugee camps in  
457 Bangladesh and beyond: A modeling study. *PLoS Med* 2020; **17**(6): e1003144-e.
- 458 57. MSF responds as COVID-19 arrives in Jordan's largest refugee camp.  
459 [https://reliefweb.int/report/jordan/msf-responds-covid-19-arrives-jordan-s-largest-refugee-](https://reliefweb.int/report/jordan/msf-responds-covid-19-arrives-jordan-s-largest-refugee-camp#:~:text=One%20month%20after%20the%20first,treatment%20centre%20in%20the%20camp.&text=Patients%20in%20a%20severe%20or,designated%20Ministry%20of%20Health%20hospitals.)  
460 [camp#:~:text=One%20month%20after%20the%20first,treatment%20centre%20in%20the%20camp.](https://reliefweb.int/report/jordan/msf-responds-covid-19-arrives-jordan-s-largest-refugee-camp#:~:text=One%20month%20after%20the%20first,treatment%20centre%20in%20the%20camp.&text=Patients%20in%20a%20severe%20or,designated%20Ministry%20of%20Health%20hospitals.)  
461 [&text=Patients%20in%20a%20severe%20or,designated%20Ministry%20of%20Health%20hospitals.](https://reliefweb.int/report/jordan/msf-responds-covid-19-arrives-jordan-s-largest-refugee-camp#:~:text=One%20month%20after%20the%20first,treatment%20centre%20in%20the%20camp.&text=Patients%20in%20a%20severe%20or,designated%20Ministry%20of%20Health%20hospitals.)  
462 (accessed 20 November 2020).
- 463 58. U.N. steps up COVID-19 measures at Syrian refugee camps in Jordan.  
464 [https://uk.reuters.com/article/uk-health-coronavirus-jordan-camp/u-n-steps-up-covid-19-measures-](https://uk.reuters.com/article/uk-health-coronavirus-jordan-camp/u-n-steps-up-covid-19-measures-at-syrian-refugee-camps-in-jordan-idUKKBN26310E)  
465 [at-syrian-refugee-camps-in-jordan-idUKKBN26310E](https://uk.reuters.com/article/uk-health-coronavirus-jordan-camp/u-n-steps-up-covid-19-measures-at-syrian-refugee-camps-in-jordan-idUKKBN26310E) (accessed 20 November 2020).
- 466 59. COVID-19 Cases Confirmed in Za'atari and Azraq Refugee Camps.  
467 [https://www.unhcr.org/jo/13759-covid-19-cases-confirmed-in-zaatari-and-azraq-refugee-](https://www.unhcr.org/jo/13759-covid-19-cases-confirmed-in-zaatari-and-azraq-refugee-camps.html)  
468 [camps.html](https://www.unhcr.org/jo/13759-covid-19-cases-confirmed-in-zaatari-and-azraq-refugee-camps.html) (accessed 20 November 2020).
- 469 60. Sleeman KE, Davies JM, Verne J, Gao W, Higginson IJ. The changing demographics of  
470 inpatient hospice death: Population-based cross-sectional study in England, 1993-2012. *Palliat Med*  
471 2016; **30**(1): 45-53.

472



473 **Table 1.** Demographic characteristics of deaths in Jordan, 2005-2016 (n=143215).

| Variables                                    | 2005-2016   |      | 2005-2007   |      | 2008-2010   |      | 2011-2013   |      | 2014-2016   |      |
|--|-------------|------|-------------|------|-------------|------|-------------|------|-------------|------|
| N  | 143215      | %    | 23281       | %    | 30639       | %    | 40661       | %    | 48634       | %    |
| Age, mean (SD)                               | 65.9 (17.0) |      | 65.4 (16.7) |      | 65.7 (16.9) |      | 66.3 (17.0) |      | 66.0 (17.3) |      |
| Age group                                    |             |      |             |      |             |      |             |      |             |      |
| 18-24  | 3566        | 2.5  | 596         | 2.6  | 763         | 2.5  | 935         | 2.3  | 1272        | 2.6  |
| 25-54  | 28701       | 20.0 | 4432        | 19.0 | 6101        | 19.9 | 8120        | 20.0 | 10048       | 20.7 |
| 55-64  | 23223       | 16.2 | 4307        | 18.5 | 5035        | 16.4 | 6224        | 15.3 | 7657        | 15.7 |
| 65-74  | 38123       | 26.6 | 6656        | 28.6 | 8650        | 28.2 | 10873       | 26.7 | 11944       | 24.6 |
| 75-84  | 34257       | 23.9 | 5090        | 21.9 | 7045        | 23.0 | 9993        | 24.6 | 12129       | 24.9 |
| 85+  | 15345       | 10.7 | 2200        | 9.4  | 3045        | 9.9  | 4516        | 11.1 | 5584        | 11.5 |
| Gender                                       |             |      |             |      |             |      |             |      |             |      |
| Men  | 81530       | 56.9 | 13444       | 57.7 | 17292       | 56.4 | 23110       | 56.8 | 27684       | 56.9 |
| Women  | 61685       | 43.1 | 9837        | 42.3 | 13347       | 43.6 | 17551       | 43.2 | 20950       | 43.1 |
| Marital status                               |             |      |             |      |             |      |             |      |             |      |
| Married                                      | 91312       | 63.8 | 15529       | 66.7 | 19483       | 63.6 | 25887       | 63.7 | 30413       | 62.5 |
| Single                                       | 8599        | 6.0  | 1572        | 6.8  | 2049        | 6.7  | 2719        | 6.7  | 2259        | 4.6  |
| Divorced                                     | 540         | 0.4  | 4           | 0.0  | 0           | 0    | 4           | 0.0  | 532         | 1.1  |
| Widowed                                      | 3961        | 2.8  | 120         | 0.5  | 31          | 0.1  | 106         | 0.3  | 3704        | 7.6  |
| Other  | 38803       | 27.1 | 6056        | 26.0 | 9076        | 29.6 | 11945       | 29.4 | 11726       | 24.1 |
| Underlying cause of death                    |             |      |             |      |             |      |             |      |             |      |
| Malignant neoplasms (except leukaemia)       | 24855       | 17.4 | 3841        | 16.5 | 5463        | 17.8 | 7323        | 18.0 | 8228        | 16.9 |
| Non-ischaemic heart                          | 15598       | 10.9 | 1716        | 7.4  | 2880        | 9.4  | 4853        | 11.9 | 6149        | 12.6 |
| Cerebrovascular                              | 17823       | 12.4 | 3131        | 13.4 | 3944        | 12.9 | 4690        | 11.5 | 6058        | 12.5 |
| Chronic ischaemic heart                      | 19498       | 13.6 | 4014        | 17.2 | 4662        | 15.2 | 5214        | 12.8 | 5608        | 11.5 |
| Atherosclerosis                              | 9526        | 6.7  | 1231        | 5.3  | 1756        | 5.7  | 2490        | 6.1  | 4049        | 8.3  |
| Renal failure                                | 4712        | 3.3  | 704         | 3.0  | 891         | 2.9  | 1271        | 3.1  | 1846        | 3.8  |
| Liver diseases                               | 5074        | 3.5  | 932         | 4.0  | 1074        | 3.5  | 1404        | 3.5  | 1664        | 3.4  |
| Lung diseases                                | 4796        | 3.3  | 1027        | 4.4  | 1051        | 3.4  | 1264        | 3.1  | 1454        | 3.0  |
| Haemorrhagic fevers                          | 2736        | 1.9  | 321         | 1.4  | 481         | 1.6  | 779         | 1.9  | 1155        | 2.4  |
| Leukaemia                                    | 2198        | 1.5  | 394         | 1.7  | 548         | 1.8  | 657         | 1.6  | 599         | 1.2  |
| Degenerative CNS                             | 645         | 0.5  | 101         | 0.4  | 139         | 0.5  | 194         | 0.5  | 211         | 0.4  |
| Musculoskeletal disorders                    | 457         | 0.3  | 88          | 0.4  | 132         | 0.4  | 124         | 0.3  | 113         | 0.2  |
| Congenital malformation                      | 334         | 0.2  | 50          | 0.2  | 76          | 0.2  | 96          | 0.2  | 112         | 0.2  |
| Injury                                       | 189         | 0.1  | 18          | 0.1  | 25          | 0.1  | 49          | 0.1  | 97          | 0.2  |
| Inflammatory CNS                             | 278         | 0.2  | 41          | 0.2  | 53          | 0.2  | 91          | 0.2  | 93          | 0.2  |
| Dementia                                     | 301         | 0.2  | 112         | 0.5  | 79          | 0.3  | 59          | 0.1  | 51          | 0.1  |
| Tuberculosis                                 | 212         | 0.1  | 57          | 0.2  | 70          | 0.2  | 56          | 0.1  | 29          | 0.1  |
| HIV  | 29          | 0.0  | 8           | 0.0  | 6           | 0.0  | 3           | 0.0  | 12          | 0.0  |
| Birth trauma, low birth weight & prematurity | 4           | 0.0  | 2           | 0.0  | 0           | 0.0  | 0           | 0.0  | 2           | 0.0  |
| Malnutrition                                 | 5           | 0.0  | 0           | 0.0  | 2           | 0.0  | 2           | 0.0  | 1           | 0.0  |
| Diseases not stated above                    | 33945       | 23.7 | 5493        | 23.6 | 7307        | 23.8 | 10042       | 24.7 | 11103       | 22.8 |
| County of origin                             |             |      |             |      |             |      |             |      |             |      |
| Jordanian                                    | 133440      | 93.2 | 21768       | 93.5 | 28665       | 93.6 | 37744       | 92.8 | 45263       | 93.1 |
| Non-Jordanian                                | 9775        | 6.8  | 1513        | 6.5  | 1974        | 6.4  | 2917        | 7.2  | 3371        | 6.9  |
| Place of death                               |             |      |             |      |             |      |             |      |             |      |
| Hospital                                     | 134222      | 93.7 | 19786       | 85.0 | 27528       | 89.8 | 38840       | 95.5 | 48068       | 98.8 |
| Non-hospital                                 | 8993        | 6.3  | 3495        | 15.0 | 3111        | 10.2 | 1821        | 4.5  | 566         | 1.2  |

**Table 2.** Odds ratios (ORs) and 95% confidence intervals (CIs) for variables associated with hospital deaths for Jordanian decedents in 2008-2010, 2011-2013, and 2014-2016 compared with 2005-2007.

|  | 2008-2010 compared with 2005-2007 |           |         | 2011-2013 compared with 2005-2007 |           |         | 2014-2016 compared with 2005-2007 |           |         |
|--|-----------------------------------|-----------|---------|-----------------------------------|-----------|---------|-----------------------------------|-----------|---------|
|  | OR                                | 95% CI    | P value | OR                                | 95% CI    | P value | OR                                | 95% CI    | P value |
| <b>Age group (years)</b>                     |                                   |           |         |                                   |           |         |                                   |           |         |
| 18-24  | 1.00                              | -         | -       | 1.00                              | -         | -       | 1.00                              | -         | -       |
| 25-54  | 1.02                              | 0.97-1.07 | 1.00    | 1.05                              | 1.01-1.10 | 0.05    | 0.94*                             | 0.91-0.97 | <0.001  |
| 55-64  | 0.99                              | 0.94-1.04 | 1.00    | 1.00                              | 0.96-1.05 | 1.00    | 0.87*                             | 0.84-0.90 | <0.001  |
| 65-74  | 1.02                              | 0.97-1.07 | 1.00    | 1.03                              | 0.98-1.07 | 1.00    | 0.86*                             | 0.83-0.89 | <0.001  |
| 75-84  | 1.04                              | 0.99-1.09 | 1.00    | 1.08*                             | 1.03-1.13 | <0.001  | 0.91*                             | 0.88-0.94 | <0.001  |
| 85+  | 1.04                              | 0.98-1.10 | 1.00    | 1.09*                             | 1.04-1.14 | <0.001  | 0.91*                             | 0.88-0.95 | <0.001  |
| <b>Gender</b>                                |                                   |           |         |                                   |           |         |                                   |           |         |
| Women  | 1.00                              | -         | -       | 1.00                              | -         | -       | 1.00                              | -         | -       |
| Men  | 0.99                              | 0.97-1.00 | 0.42    | 1.00                              | 0.99-1.02 | 1.00    | 1.03*                             | 1.01-1.04 | <0.001  |
| <b>Marital status</b>                        |                                   |           |         |                                   |           |         |                                   |           |         |
| Single                                       | 1.00                              | -         | -       | 1.00                              | -         | -       | 1.00                              | -         | -       |
| Married                                      | 1.00                              | 0.97-1.03 | 1.00    | 0.98                              | 0.96-1.00 | 0.94    | 1.10*                             | 1.08-1.13 | <0.001  |
| Divorced                                     | NA                                | NA        | NA      | NA                                | NA        | NA      | 1.47*                             | 1.39-1.56 | <0.001  |
| Widowed                                      | NA                                | NA        | NA      | NA                                | NA        | NA      | 1.49*                             | 1.44-1.54 | <0.001  |
| Other  | 1.00                              | 0.96-1.03 | 1.00    | 0.98                              | 0.95-1.01 | 1.00    | 1.06*                             | 1.03-1.09 | <0.001  |
| <b>Underlying cause of death</b>             |                                   |           |         |                                   |           |         |                                   |           |         |
| Other  | 1.00                              | -         | -       | 1.00                              | -         | -       | 1.00                              | -         | -       |
| Malignant neoplasms (except leukaemia)       | 1.03*                             | 1.01-1.05 | 0.007   | 1.01                              | 1.00-1.03 | 1.00    | 1.01                              | 1.00-1.03 | 1.00    |
| Non-ischaemic heart                          | 1.05*                             | 1.03-1.08 | <0.001  | 1.09*                             | 1.07-1.11 | <0.001  | 1.11*                             | 1.09-1.13 | <0.001  |
| Cerebrovascular                              | 0.99                              | 0.97-1.01 | 1.00    | 0.94*                             | 0.92-0.96 | <0.001  | 0.98                              | 0.96-0.99 | 0.01    |
| Chronic ischaemic heart                      | 0.98                              | 0.96-1.00 | 0.15    | 0.93*                             | 0.92-0.95 | <0.001  | 0.93*                             | 0.92-0.95 | <0.001  |
| Atherosclerosis                              | 1.03                              | 1.00-1.06 | 0.15    | 1.03                              | 1.00-1.06 | 0.06    | 1.10*                             | 1.08-1.13 | <0.001  |
| Renal failure                                | 1.00                              | 0.96-1.04 | 1.00    | 0.99                              | 0.96-1.02 | 1.00    | 1.05*                             | 1.02-1.08 | <0.001  |
| Liver diseases                               | 0.97                              | 0.94-1.00 | 0.37    | 0.95*                             | 0.92-0.97 | <0.001  | 0.96*                             | 0.94-0.99 | <0.001  |
| Lung diseases                                | 0.94*                             | 0.91-0.97 | <0.001  | 0.90*                             | 0.88-0.93 | <0.001  | 0.92*                             | 0.90-0.95 | <0.001  |
| Haemorrhagic fevers                          | 1.04                              | 0.98-1.09 | 1.00    | 1.05                              | 1.01-1.09 | 0.07    | 1.09*                             | 1.06-1.13 | <0.001  |
| Leukaemia                                    | 1.02                              | 0.97-1.07 | 1.00    | 0.97                              | 0.93-1.02 | 1.00    | 0.93*                             | 0.89-0.97 | <0.001  |
| Degenerative CNS                             | 1.01                              | 0.92-1.12 | 1.00    | 1.02                              | 0.94-1.10 | 1.00    | 1.04                              | 0.97-1.11 | 1.00    |
| Musculoskeletal disorders                    | 1.04                              | 0.94-1.14 | 1.00    | 0.94                              | 0.86-1.03 | 1.00    | 0.90                              | 0.83-0.99 | 0.09    |
| Congenital malformation                      | 1.04                              | 0.90-1.19 | 1.00    | 1.04                              | 0.93-1.16 | 1.00    | 1.04                              | 0.94-1.15 | 1.00    |
| Injury                                       | 1.05                              | 0.81-1.35 | 1.00    | 1.16                              | 0.98-1.38 | 0.48    | 1.18*                             | 1.06-1.33 | <0.001  |
| Inflammatory CNS                             | 0.99                              | 0.85-1.16 | 1.00    | 1.03                              | 0.91-1.17 | 1.00    | 1.00                              | 0.90-1.13 | 1.00    |
| Dementia                                     | 0.85*                             | 0.76-0.94 | 0.001   | 0.74*                             | 0.67-0.82 | <0.001  | 0.73*                             | 0.66-0.80 | <0.001  |
| Tuberculosis                                 | 0.94                              | 0.82-1.07 | 1.00    | 0.82*                             | 0.72-0.93 | <0.001  | 0.69*                             | 0.60-0.80 | <0.001  |
| HIV  | 0.70                              | 0.46-1.09 | 0.94    | 0.58                              | 0.37-0.90 | 0.03    | 0.91                              | 0.68-1.20 | 1.00    |
| Birth trauma, low birth weight & prematurity | 0.58                              | 0.16-2.13 | 1.00    | 0.53                              | 0.15-1.84 | 1.00    | 0.53                              | 0.17-1.71 | 1.00    |
| Malnutrition                                 | 1.55                              | 0.62-3.87 | 1.00    | 1.33                              | 0.55-3.20 | 1.00    | 1.01                              | 0.31-3.23 | 1.00    |

ORs were estimated from binomial logistic regression models.


\*P value  $\leq$  0.008 (Bonferroni correction was applied to adjust for family-wise error rate 0.05/6)

**Table 3.** Odds ratios (ORs) and 95% confidence intervals (CIs) for variables associated with hospital deaths for non-Jordanian decedents in 2008-2010, 2011-2013, and 2014-2016 compared with 2005-2007.

|  | 2008-2010 compared with 2005-2007 |           |         | 2011-2013 compared with 2005-2007 |           |         | 2014-2016 compared with 2005-2007 |           |         |
|--|-----------------------------------|-----------|---------|-----------------------------------|-----------|---------|-----------------------------------|-----------|---------|
|  | OR                                | 95% CI    | P value | OR                                | 95% CI    | P value | OR                                | 95% CI    | P value |
| <b>Age group (years)</b>                     |                                   |           |         |                                   |           |         |                                   |           |         |
| 18-24  | 1.00                              | -         | -       | 1.00                              | -         | -       | 1.00                              | -         | -       |
| 25-54  | 1.18                              | 1.03-1.36 | 0.05    | 1.01                              | 0.92-1.11 | 1.00    | 0.97                              | 0.89-1.06 | 1.00    |
| 55-64  | 1.00                              | 0.89-1.12 | 1.00    | 0.99                              | 0.90-1.10 | 1.00    | 0.96                              | 0.88-1.06 | 1.00    |
| 65-74  | 1.01                              | 0.90-1.14 | 1.00    | 1.04                              | 0.94-1.15 | 1.00    | 1.01                              | 0.92-1.11 | 1.00    |
| 75-84  | 1.01                              | 0.90-1.14 | 1.00    | 1.04                              | 0.93-1.15 | 1.00    | 1.03                              | 0.94-1.13 | 1.00    |
| 85+  | 1.00                              | 0.89-1.13 | 1.00    | 0.99                              | 0.88-1.11 | 1.00    | 1.02                              | 0.92-1.13 | 1.00    |
| <b>Gender</b>                                |                                   |           |         |                                   |           |         |                                   |           |         |
| Women  | 1.00                              | -         | -       | 1.00                              | -         | -       | 1.00                              | -         | -       |
| Men  | 1.01                              | 0.85-1.19 | 1.00    | 1.00                              | 0.97-1.05 | 1.00    | 1.02                              | 0.99-1.06 | 1.00    |
| <b>Marital status</b>                        |                                   |           |         |                                   |           |         |                                   |           |         |
| Single                                       | 1.00                              | -         | -       | 1.00                              | -         | -       | 1.00                              | -         | -       |
| Married                                      | 0.82                              | 0.43-1.60 | 1.00    | 1.05                              | 0.94-1.18 | 1.00    | 1.16                              | 1.03-1.30 | 0.03    |
| Divorced                                     | 1.00                              | 0.88-1.15 | 1.00    | 1.09                              | 0.69-1.72 | 1.00    | 1.25                              | 0.79-1.96 | 1.00    |
| Widowed                                      | 1.74*                             | 1.52-1.98 | <0.001  | 0.99                              | 0.87-1.14 | 1.00    | 1.02                              | 0.88-1.17 | 1.00    |
| Other  | 1.01                              | 0.88-1.15 | 1.00    | 1.35*                             | 1.21-1.51 | <0.001  | 1.69*                             | 1.51-1.89 | <0.001  |
| <b>Underlying cause of death</b>             |                                   |           |         |                                   |           |         |                                   |           |         |
| Other  | 1.00                              | -         | -       | 1.00                              | -         | -       | 1.00                              | -         | -       |
| Malignant neoplasms (except leukaemia)       | 1.07                              | 1.00-1.14 | 0.13    | 0.98                              | 0.93-1.04 | 1.00    | 1.03                              | 0.98-1.08 | 1.00    |
| Non-ischaemic heart                          | 1.05                              | 0.95-1.16 | 1.00    | 1.06                              | 0.98-1.15 | 1.00    | 1.06                              | 1.00-1.14 | 0.40    |
| Cerebrovascular                              | 0.49                              | 0.16-1.51 | 1.00    | 0.94                              | 0.87-1.00 | 0.42    | 0.99                              | 0.93-1.05 | 1.00    |
| Chronic ischaemic heart                      | 1.00                              | 0.93-1.08 | 1.00    | 0.91                              | 0.85-0.97 | 0.01    | 0.98                              | 0.93-1.04 | 1.00    |
| Atherosclerosis                              | 0.99                              | 0.95-1.04 | 1.00    | 0.95                              | 0.88-1.04 | 1.00    | 1.05                              | 0.98-1.12 | 1.00    |
| Renal failure                                | 0.97                              | 0.86-1.10 | 1.00    | 0.91                              | 0.82-1.02 | 0.90    | 0.98                              | 0.89-1.08 | 1.00    |
| Liver diseases                               | 1.01                              | 0.91-1.11 | 1.00    | 0.93                              | 0.85-1.03 | 1.00    | 0.98                              | 0.90-1.06 | 1.00    |
| Lung diseases                                | 0.88                              | 0.77-1.00 | 0.25    | 0.81*                             | 0.72-0.92 | <0.001  | 0.88                              | 0.80-0.97 | 0.03    |
| Haemorrhagic fevers                          | 0.92                              | 0.52-1.61 | 1.00    | 0.99                              | 0.88-1.10 | 1.00    | 1.00                              | 0.90-1.11 | 1.00    |
| Leukaemia                                    | 1.03                              | 0.92-1.15 | 1.00    | 0.95                              | 0.86-1.05 | 1.00    | 0.91                              | 0.81-1.01 | 0.41    |
| Degenerative CNS                             | 0.94                              | 0.71-1.26 | 1.00    | 0.95                              | 0.68-1.31 | 1.00    | 0.88                              | 0.63-1.24 | 1.00    |
| Musculoskeletal disorders                    | 1.08                              | 0.82-1.41 | 1.00    | 0.83                              | 0.61-1.12 | 1.00    | 0.77                              | 0.57-1.06 | 0.87    |
| Congenital malformation                      | 1.02                              | 0.95-1.10 | 1.00    | 0.76                              | 0.53-1.09 | 1.00    | 0.89                              | 0.68-1.16 | 1.00    |
| Injury                                       | 1.04                              | 0.81-1.33 | 1.00    | 1.37                              | 0.60-3.16 | 1.00    | 1.16                              | 0.54-2.49 | 1.00    |
| Inflammatory CNS                             | 1.32                              | 0.69-2.54 | 1.00    | 0.94                              | 0.75-1.19 | 1.00    | 0.95                              | 0.76-1.18 | 1.00    |
| Dementia                                     | 1.02                              | 0.70-1.49 | 1.00    | 0.68                              | 0.34-1.34 | 1.00    | 0.82                              | 0.48-1.41 | 1.00    |
| Tuberculosis                                 | 1.04                              | 0.80-1.34 | 1.00    | 0.92                              | 0.69-1.22 | 1.00    | 0.88                              | 0.66-1.17 | 1.00    |
| HIV  | 1.04                              | 0.91-1.19 | 1.00    | 1.57                              | 0.48-5.09 | 1.00    | 1.42                              | 0.66-3.03 | 1.00    |
| Birth trauma, low birth weight & prematurity | 1.04                              | 0.95-1.15 | 1.00    | 0.44                              | 0.14-1.44 | 1.00    | 0.85                              | 0.46-1.58 | 1.00    |
| Malnutrition                                 | NA                                | NA        | NA      | NA                                | NA        | NA      | NA                                | NA        | NA      |

ORs were estimated from binomial logistic regression models.

\*P value  $\leq$  0.008 (Bonferroni correction was applied to adjust for family-wise error rate 0.05/6)



**Figure 1.** Percentage of deaths registered in Jordan for whom the decedent was Jordanian and non-Jordanian by underlying cause of death, 2005-2016.



**Figure 2.** Trend of Jordanian and non-Jordanian deaths by place of death, 2005-2016.

**Appendix 1. Demographic characteristics of deaths in Jordan across 12 years, 2005-2016 (n=143215).**

|  | 2005 | 2006 | 2007 | 2008 | 2009  | 2010  | 2011  | 2012  | 2013  | 2014  | 2015  | 2016  |
|--|------|------|------|------|-------|-------|-------|-------|-------|-------|-------|-------|
| N                                      | 6792 | 7988 | 8501 | 8207 | 10098 | 12334 | 12225 | 13373 | 15063 | 15863 | 15753 | 17018 |
| Crude death rate per 1,000*            | 1.19 | 1.30 | 1.36 | 1.25 | 1.46  | 1.70  | 1.60  | 1.65  | 1.77  | 1.78  | 1.70  | 1.78  |
| Age group (years) %                    |      |      |      |      |       |       |       |       |       |       |       |       |
| 18-24                                  | 2.5  | 2.2  | 2.9  | 2.4  | 2.2   | 2.8   | 2.0   | 2.4   | 2.4   | 2.7   | 2.5   | 2.7   |
| 25-54                                  | 18.5 | 19.3 | 19.2 | 19.5 | 19.1  | 20.8  | 18.4  | 20.4  | 20.9  | 20.9  | 20.6  | 20.5  |
| 55-64                                  | 18.8 | 18.1 | 18.6 | 17.0 | 16.5  | 15.9  | 15.8  | 15.4  | 14.9  | 15.7  | 15.5  | 16.1  |
| 65-74                                  | 29.4 | 28.8 | 27.7 | 29.1 | 28.4  | 27.5  | 27.6  | 26.8  | 26.0  | 24.5  | 24.6  | 24.6  |
| 75-84                                  | 21.1 | 22.0 | 22.4 | 22.4 | 23.5  | 23.0  | 24.9  | 24.5  | 24.4  | 24.9  | 25.1  | 24.8  |
| 85+                                    | 9.7  | 9.6  | 9.1  | 9.5  | 10.3  | 9.9   | 11.3  | 10.5  | 11.5  | 11.4  | 11.8  | 11.3  |
| Gender %                               |      |      |      |      |       |       |       |       |       |       |       |       |
| Men                                    | 57.8 | 58.0 | 57.5 | 56.2 | 56.5  | 56.5  | 55.8  | 56.4  | 58.0  | 57.2  | 56.7  | 56.9  |
| Women                                  | 42.2 | 42.0 | 42.5 | 43.8 | 43.5  | 43.5  | 44.2  | 43.6  | 42.0  | 42.8  | 43.3  | 43.1  |
| Marital status %                       |      |      |      |      |       |       |       |       |       |       |       |       |
| Married                                | 67.9 | 67.2 | 65.3 | 64.6 | 64.0  | 62.5  | 63.3  | 63.6  | 64.0  | 62.5  | 63.6  | 61.6  |
| Single                                 | 6.8  | 6.4  | 7.1  | 6.2  | 5.9   | 7.6   | 6.0   | 6.9   | 7.1   | 7.2   | 7.1   | 0.0   |
| Divorced                               | 0.0  | 0.0  | 0.0  | 0.0  | 0.0   | 0.0   | 0.0   | 0.0   | 0.0   | 0.0   | 0.0   | 3.1   |
| Widowed                                | 0.6  | 0.7  | 0.3  | 0.4  | 0.0   | 0.0   | 0.0   | 0.4   | 0.4   | 0.1   | 0.2   | 21.5  |
| Other                                  | 24.6 | 25.7 | 27.4 | 28.8 | 30.0  | 29.8  | 30.7  | 29.1  | 28.5  | 30.3  | 29.0  | 13.9  |
| Underlying cause of death %            |      |      |      |      |       |       |       |       |       |       |       |       |
| Haemorrhagic fevers                    | 1.0  | 1.4  | 1.7  | 1.6  | 1.7   | 1.4   | 1.7   | 2.0   | 2.0   | 1.9   | 2.5   | 2.7   |
| Tuberculosis                           | 0.2  | 0.3  | 0.3  | 0.3  | 0.2   | 0.2   | 0.2   | 0.1   | 0.1   | 0.1   | 0.0   | 0.1   |
| HIV                                    | 0.1  | 0.0  | 0.0  | 0.0  | 0.0   | 0.0   | 0.0   | 0.0   | 0.0   | 0.0   | 0.0   | 0.0   |
| Malignant neoplasms (except leukaemia) | 16.5 | 16.4 | 16.5 | 18.8 | 17.3  | 17.7  | 18.2  | 18.2  | 17.7  | 17.0  | 17.1  | 16.6  |
| Leukaemia                              | 1.4  | 2.0  | 1.6  | 2.0  | 2.0   | 1.5   | 1.8   | 1.7   | 1.4   | 1.3   | 1.4   | 1.0   |
| Dementia                               | 0.5  | 0.6  | 0.4  | 0.4  | 0.2   | 0.2   | 0.1   | 0.2   | 0.1   | 0.2   | 0.1   | 0.1   |
| Inflammatory CNS                       | 0.1  | 0.2  | 0.2  | 0.2  | 0.1   | 0.2   | 0.3   | 0.2   | 0.2   | 0.2   | 0.2   | 0.2   |
| Degenerative CNS                       | 0.4  | 0.6  | 0.4  | 0.5  | 0.5   | 0.4   | 0.6   | 0.4   | 0.5   | 0.5   | 0.4   | 0.4   |
| Cerebrovascular                        | 13.9 | 13.1 | 13.4 | 13.0 | 14.3  | 11.6  | 12.0  | 11.4  | 11.3  | 11.6  | 12.5  | 13.2  |
| Non-ischaemic heart                    | 8.3  | 6.9  | 7.1  | 7.9  | 8.1   | 11.5  | 11.5  | 11.4  | 12.7  | 13.1  | 11.7  | 13.1  |
| Chronic ischaemic heart                | 16.1 | 17.2 | 18.2 | 16.4 | 15.4  | 14.3  | 13.8  | 12.8  | 12.1  | 11.8  | 11.5  | 11.3  |
| Lung diseases                          | 4.4  | 4.3  | 4.6  | 3.8  | 3.6   | 3.1   | 3.3   | 3.2   | 2.9   | 2.7   | 3.2   | 3.0   |
| Liver diseases                         | 3.7  | 4.4  | 3.8  | 3.7  | 3.6   | 3.3   | 3.7   | 3.5   | 3.2   | 3.2   | 3.7   | 3.4   |
| Renal failure                          | 3.5  | 3.2  | 2.4  | 2.8  | 3.0   | 2.9   | 2.7   | 3.5   | 3.2   | 3.7   | 3.9   | 3.8   |

|  |      |      |      |      |      |      |      |      |      |      |      |      |
|--|------|------|------|------|------|------|------|------|------|------|------|------|
| Birth trauma, low birth weight & prematurity | 0·0  | 0·0  | 0·0  | 0·0  | 0·0  | 0·0  | 0·0  | 0·0  | 0·0  | 0·0  | 0·0  | 0·0  |
| Congenital malformation                      | 0·2  | 0·2  | 0·2  | 0·3  | 0·3  | 0·2  | 0·3  | 0·2  | 0·2  | 0·3  | 0·2  | 0·2  |
| Injury                                       | 0·1  | 0·1  | 0·1  | 0·0  | 0·1  | 0·1  | 0·0  | 0·1  | 0·2  | 0·2  | 0·1  | 0·3  |
| Atherosclerosis                              | 5·9  | 5·3  | 4·8  | 6·0  | 5·7  | 5·5  | 6·1  | 6·2  | 6·1  | 8·0  | 8·8  | 8·2  |
| Musculoskeletal disorders                    | 0·3  | 0·4  | 0·4  | 0·5  | 0·4  | 0·5  | 0·3  | 0·3  | 0·3  | 0·2  | 0·2  | 0·2  |
| Malnutrition                                 | 0·0  | 0·0  | 0·0  | 0·0  | 0·0  | 0·0  | 0·0  | 0·0  | 0·0  | 0·0  | 0·0  | 0·0  |
| Diseases not stated above                    | 23·3 | 23·5 | 23·9 | 22·0 | 23·5 | 25·3 | 23·5 | 24·6 | 25·8 | 24·1 | 22·3 | 22·2 |
| County of origin %                           |      |      |      |      |      |      |      |      |      |      |      |      |
| Jordanian                                    | 94·7 | 93·1 | 93·0 | 92·1 | 93·9 | 94·2 | 94·4 | 91·8 | 92·5 | 93·3 | 92·6 | 93·3 |
| Non-Jordanian                                | 5·3  | 6·9  | 7·0  | 7·9  | 6·1  | 5·8  | 5·6  | 8·2  | 7·5  | 6·7  | 7·4  | 6·7  |
| Place of death %                             |      |      |      |      |      |      |      |      |      |      |      |      |
| Hospital                                     | 83·0 | 87·1 | 84·6 | 86·8 | 92·3 | 89·8 | 93·9 | 95·2 | 97·1 | 99·3 | 98·4 | 98·9 |
| Non-hospital                                 | 17·0 | 12·9 | 15·4 | 13·2 | 7·7  | 10·2 | 6·1  | 4·8  | 2·9  | 0·7  | 1·6  | 1·1  |

\*the total number of deaths to residents divided by the total population in Jordan each year (based on the population data for Jordan from the World Bank dataset: <https://data.worldbank.org/indicator/SP.POP.TOTL?locations=JO>) and multiplied by 1,000.